Assembly Biosciences Profit Margin

The latest profit margin for ASMB is -0.1% as of June 2026. That compares with -274.36% in the prior-year period — up 100.0% year over year. That is below the Healthcare sector average of 21.34%. Investors often review this figure alongside Assembly Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, ASMB's profit margin moved from -274.36% to -0.1% — a 100.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Assembly Biosciences's valuation or profitability profile.

Against Healthcare companies, ASMB currently prints -0.1% for profit margin, while the sector average sits near 21.34%. That is roughly 100.5% below the sector mean. Large gaps often invite a closer look at Assembly Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Assembly Biosciences converts resources into returns. At -0.1%, ASMB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -274.36% in the prior-year period — up 100.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting ASMB's profit margin (-0.1%), review year-over-year change from -274.36%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.